01.12.2017 | Research article | Ausgabe 1/2017 Open Access

Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
- Zeitschrift:
- BMC Cancer > Ausgabe 1/2017
Electronic supplementary material
Background
Methods
Patient selection
Tissue microarray and immunohistochemistry
Statistical analysis
Results
CCR7 staining and cut off point choosing
Patient baseline characteristics and its association with dichotomous CCR7 expression
Characteristics
|
Patients
|
Tumoral CCR7 expression
|
|||
---|---|---|---|---|---|
n
|
%
|
low
|
high
|
P-value
|
|
No. of patients
|
110
|
100
|
53
|
57
|
|
Age, years, mean (SD)
|
57.5 (11.9)
|
||||
Men
|
79
|
71.8
|
|||
ECOG PS
|
0.198
c
|
||||
0
|
81
|
73.6
|
42
|
39
|
|
1
|
29
|
26.4
|
11
|
18
|
|
Prior nephrectomy
|
N/A
|
||||
Yes
|
110
|
100.0
|
|||
No
|
0
|
0.0
|
|||
Histology
|
0.086
c
|
||||
Clear cell
|
88
|
80.0
|
46
|
42
|
|
Non-clear cell type
|
22
|
20.0
|
7
|
15
|
|
Papillary
|
15
|
13.6
|
|||
Chromophobe
|
2
|
1.8
|
|||
Collecting duct
|
2
|
1.8
|
|||
Unclassified
|
3
|
2.7
|
|||
Fuhrman grade (7 excluded)
|
0.147
d
|
||||
1
|
2
|
1.8
|
2
|
0
|
|
2
|
53
|
48.2
|
28
|
25
|
|
3
|
41
|
37.3
|
18
|
23
|
|
4
|
7
|
6.4
|
5
|
2
|
|
TNM stage at initial diagnosis
|
0.004
c
|
||||
I-III
|
51
|
46.4
|
32
|
19
|
|
IV
|
59
|
53.6
|
21
|
38
|
|
Site of metastatic disease
a
|
|||||
Lung
|
82
|
74.5
|
|||
Liver
|
13
|
11.8
|
|||
Bone
|
18
|
16.4
|
|||
Lymph node
|
29
|
26.4
|
|||
Adrenal gland
|
8
|
7.3
|
|||
Brain and others
|
15
|
13.6
|
|||
Lymph node involvement
a
|
0.031
c
|
||||
No
|
81
|
73.6
|
44
|
37
|
|
Yes
|
29
|
26.4
|
9
|
20
|
|
No. of metastatic sites
a
|
0.070
c
|
||||
1
|
76
|
69.1
|
41
|
35
|
|
≥ 2
|
34
|
30.9
|
12
|
22
|
|
Tyrosine kinase inhibitors
|
0.254
c
|
||||
Sunitinib
|
73
|
66.4
|
38
|
35
|
|
Sorafenib
|
37
|
33.6
|
15
|
22
|
|
Heng’s risk group
|
0.271
d
|
||||
Favorable
|
22
|
20
|
12
|
10
|
|
Intermediate
|
60
|
54.5
|
30
|
30
|
|
Poor
|
28
|
25.5
|
11
|
17
|
|
Best response (3 not assessable)
|
<0.001
d
|
||||
Partial response
|
27
|
25.2
|
18
|
9
|
|
Stable disease for ≥3 months
|
57
|
53.3
|
30
|
27
|
|
Progressive disease
b
|
23
|
21.5
|
2
|
21
|
Impact of baseline characteristics, including dichotomous CCR7 expression, on OS in mRCC patients receiving TKIs
Variables
|
OS (
n = 110)
|
PFS (
n = 107)
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Original
|
Variables selected
|
Bootstrap
c
|
Original
|
Variables selected
|
Bootstrap
c
|
|||||
HR (95%CI)
|
P-value
b
|
HR (95%CI)
|
P-value
b
|
P-value
b
|
HR (95%CI)
|
P-value
b
|
HR (95%CI)
|
P-value
b
|
P-value
b
|
|
Histology
|
||||||||||
Non-clear cell vs clear cell
|
2.325 (1.293–4.181)
|
0.005
|
2.108 (1.191–3.732)
|
0.010
|
0.011
|
1.717 (1.008–2.926)
|
0.047
|
1.606 (0.952–2.710)
|
0.076
|
0.087
|
TNM stage at initial diagnosis
|
||||||||||
IV vs I–III
|
0.990 (0.565–1.736)
|
0.972
|
0.988 (0.599–1.631)
|
0.963
|
||||||
No. of metastatic sites
a
|
||||||||||
≥ 2 vs 1
|
1.465 (0.867–2.477)
|
0.154
|
1.946 (1.210–3.128)
|
0.006
|
1.817 (1.138–2.902)
|
0.012
|
0.026
|
|||
Tyrosine kinase inhibitors
|
||||||||||
Sorafenib vs Sunitinib
|
1.431 (0.861–2.381)
|
0.167
|
1.360 (0.858–2.154)
|
0.191
|
||||||
Heng’s risk group
|
<0.001
|
<0.001
|
0.005
|
0.036
|
0.011
|
0.035
|
||||
Favorable
|
reference
|
reference
|
reference
|
reference
|
||||||
Intermediate
|
1.955 (0.895–4.268)
|
2.023 (0.964–4.244)
|
1.212 (0.634–2.313)
|
1.297 (0.701–2.398)
|
||||||
Poor
|
5.654 (2.267–14.103)
|
6.760 (2.932–15.587)
|
2.432 (1.095–5.398)
|
2.771 (1.326–5.788)
|
||||||
Tumoral CCR7
|
||||||||||
High vs Low
|
2.242 (1.288–3.901)
|
0.004
|
2.256 (1.336–3.809)
|
0.002
|
0.003
|
1.782 (1.105–2.875)
|
0.018
|
1.835 (1.156–2.912)
|
0.010
|
0.013
|